311 related articles for article (PubMed ID: 26935576)
21. Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.
Cavalloni C; Rumi E; Ferretti VV; Pietra D; Roncoroni E; Bellini M; Ciboddo M; Casetti IC; Landini B; Fugazza E; Troletti D; Astori C; Cazzola M
Oncotarget; 2017 May; 8(20):33416-33421. PubMed ID: 28422716
[TBL] [Abstract][Full Text] [Related]
22. The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.
Tefferi A; Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Am J Hematol; 2019 Mar; 94(3):299-305. PubMed ID: 30516848
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
[TBL] [Abstract][Full Text] [Related]
24. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
[TBL] [Abstract][Full Text] [Related]
25. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
[TBL] [Abstract][Full Text] [Related]
26. A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients.
Zaidi U; Sufaida G; Rashid M; Kaleem B; Maqsood S; Mukry SN; Khan RZA; Munzir S; Borhany M; Shamsi TS
BMC Cancer; 2020 Mar; 20(1):205. PubMed ID: 32164591
[TBL] [Abstract][Full Text] [Related]
27. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
[TBL] [Abstract][Full Text] [Related]
28. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
Nangalia J; Massie CE; Baxter EJ; Nice FL; Gundem G; Wedge DC; Avezov E; Li J; Kollmann K; Kent DG; Aziz A; Godfrey AL; Hinton J; Martincorena I; Van Loo P; Jones AV; Guglielmelli P; Tarpey P; Harding HP; Fitzpatrick JD; Goudie CT; Ortmann CA; Loughran SJ; Raine K; Jones DR; Butler AP; Teague JW; O'Meara S; McLaren S; Bianchi M; Silber Y; Dimitropoulou D; Bloxham D; Mudie L; Maddison M; Robinson B; Keohane C; Maclean C; Hill K; Orchard K; Tauro S; Du MQ; Greaves M; Bowen D; Huntly BJP; Harrison CN; Cross NCP; Ron D; Vannucchi AM; Papaemmanuil E; Campbell PJ; Green AR
N Engl J Med; 2013 Dec; 369(25):2391-2405. PubMed ID: 24325359
[TBL] [Abstract][Full Text] [Related]
29. Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms.
Wojtaszewska M; Iwoła M; Lewandowski K
Acta Haematol; 2015; 133(2):193-8. PubMed ID: 25323779
[TBL] [Abstract][Full Text] [Related]
30. Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis.
Kong H; Liu Y; Luo S; Li Q; Wang Q
Intern Med; 2016; 55(15):1977-84. PubMed ID: 27477402
[TBL] [Abstract][Full Text] [Related]
31. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
Alshemmari SH; Rajan R; Emadi A
Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
[TBL] [Abstract][Full Text] [Related]
32. Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis.
Fan N; Tang Y; Wu Z; Guan M; Chen B; Xu X; Ma W; Xu X; Zhang X
Ann Hematol; 2018 Jul; 97(7):1193-1208. PubMed ID: 29560522
[TBL] [Abstract][Full Text] [Related]
33. [Clinical Analysis of 66 Patients with Essential Thrombocytopenia].
Zhang LJ; Shi YY; Chen Y; Gan YM; Shi WT; Chen KK; Ding BH; He ZM; Wang CL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1321-1325. PubMed ID: 32798420
[TBL] [Abstract][Full Text] [Related]
34. Comparison of JAK2
Latagliata R; Polverelli N; Tieghi A; Palumbo GA; Breccia M; Sabattini E; Villari L; Riminucci M; Valli R; Catani L; Alimena G; Ottaviani E; Fama A; Martinelli G; Perricone M; Spinsanti M; Cavo M; Vianelli N; Palandri F
Hematol Oncol; 2018 Feb; 36(1):269-275. PubMed ID: 28509339
[TBL] [Abstract][Full Text] [Related]
35. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2
Saki N; Shirzad R; Rahim F; Saki Malehi A
Clin Transl Oncol; 2017 Jul; 19(7):874-883. PubMed ID: 28205126
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan.
Kuo MC; Chuang WY; Chang H; Lin TH; Wu JH; Lin TL; Ou CW; Hung YS; Huang TY; Huang YJ; Wang PN; Shih LY
Am J Clin Pathol; 2023 May; 159(5):474-483. PubMed ID: 36857745
[TBL] [Abstract][Full Text] [Related]
37. Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis.
Zamora L; Xicoy B; Cabezón M; Fernandez C; Marcé S; Velez P; Xandri M; Gallardo D; Millá F; Feliu E; Boqué C
Leuk Lymphoma; 2015; 56(10):2973-4. PubMed ID: 25686645
[No Abstract] [Full Text] [Related]
38. Thrombin Generation Testing in Patients with Myelofibrosis.
Palova M; Slavik L; Hlusi A; Szotkowski T; Ulehlova J; Divoka M; Navratilova J; Papajik T
Clin Lab; 2018 Sep; 64(9):1373-1383. PubMed ID: 30274004
[TBL] [Abstract][Full Text] [Related]
39. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
40. Prognostication in MF: from CBC to cytogenetics to molecular markers.
Zhou A; Oh ST
Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]